Hemophilia Market Size (2024 - 2029)

Hemophilia Market Analysis

The Hemophilia Market size is estimated at USD 13.66 billion in 2024, and is expected to reach USD 17.86 billion by 2028, growing at a CAGR of 5.5% during the forecast period (2024-2028).

Certain factors driving the market’s growth include the growing prevalence of hemophilia, favorable government initiatives, and rising research and development. For instance, according to the World Federation of Hemophilia Global Report 2022, around 18,580 people were diagnosed with hemophilia in the United States in 2022. Hemophilia is a genetic blood disorder that damages the normal functionality of blood clotting and coagulation. Around 386,966 people with bleeding disorders were identified globally, of which 233,577 cases were hemophilia. Such a huge prevalence of hemophilia globally is expected to lead to increased adoption of therapies, driving market growth.

Additionally, an increase in grants for research on hemophilia is expected to contribute to market growth over the forecast period. For instance, in March 2022, a researcher from the Indiana University School of Medicine received USD 2 million from the National Heart Lung and Blood Institute to develop three major themes in a gene therapy approach that could lead to safer and potentially curative treatments for hemophilia. Such grants may lead to the development of novel therapies for hemophilia, thereby driving market growth over the forecast period.

Similarly, in January 2023, BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, publicized positive results from more than three years of follow-up from its global Phase 3 GENEr8-1 study of ROCTAVIANTM (valoctocogene roxaparvovec). It was an investigational one-time gene therapy for treating adults with severe hemophilia A. It was the largest and longest global Phase 3 study for any gene therapy in hemophilia, with 134 participants.

Moreover, rising product approvals from the US Food and Drug Administration are expected to propel market growth. For instance, in March 2022, Freeline Therapeutics Holdings PLC dosed the first patient in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for treating hemophilia B. It is a debilitating genetic bleeding disorder caused by a clotting factor IX protein deficiency.

Thus, due to the rise in hemophilia cases and the increase in product launches, coupled with research and development for hemophilia therapies, the market studied is expected to witness significant growth during the forecast period. However, the high cost of hemophilia treatment and the need for more awareness among people regarding advanced technologies are expected to hinder market growth.

Hemophilia Industry Segmentation

As per the scope of the report, hemophilia is a genetic bleeding disorder that prevents the blood from clotting normally due to a lack of enough blood-clotting proteins (clotting factors). People with hemophilia contain low levels of either factor VIII (8) or factor IX (9). The primary symptom is uncontrolled, often spontaneous bleeding in different body areas. The amount of bleeding depends on the severity of hemophilia.

The hemophilia market is segmented by disease type, therapy, product type, and geography. By disease type, the market is segmented as hemophilia A, hemophilia B, and other disease types. By therapy, the market is segmented as replacement therapy, gene therapy, and other therapies. By product type, the market is segmented as recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, and other product types. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally and offers the value (USD) for the above segments.